Hospira (NYSE:HSP) U.S. FDA Approval of Solution Version of Gemcitabine Injection

Aug 6th, 2011

Thank you for joining us. I am your host Sara Bryant at CRWE Newswire Stocks to watch

Hospira, Incorporated – symbol HSP – reported U.S. Food and Drug Administration approval of gemcitabine injection, a solution form of the drug. The solution presentations include 200 mg, 1 gm and 2 gm with a concentration of 38 milligram per milliliter.

Hospira is the first company to offer gemcitabine in a solution formulation for the U.S. market. The solution formulation is designed to improve pharmacist convenience and handling safety.

The oncology medication had U.S. sales of more than $750 million in 2010, led by Eli Lilly’s Gemzar. Hospira expects to launch the product in early September.

Hospira is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness

Thank you for tuning in, have a great day. For CRWE Newswire, Stocks to watch, I’m Sara Bryant.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.


 
Share/Bookmark
 

Category: Stock Market Videos

Tags: , , , , ,

 
 
 

  • EQCO2, Inc. Fraud Lawsuit

  • Hot stocks to watch!

    Corning Inc - GLW

    Citigroup Inc - C

    Atmel Corp - ATML

    Regions Financial Corp - RF

    Crown Equity Holdings Inc. - CRWE

    Sterling Financial Corp Wa - STSA

    Micron Technology Inc - MU

    ProShares UltraShort S&P500 ETF - SDS

    Kingdom Koncrete Inc. - KGKO

    NVIDIA Corp - NVDA

    Bucyrus International Inc - BUCY

    iShares Down Jones U.S. Real Estate Index - IYR

    Marvell Technology Group Ltd - MRVL

    SanDisk Crop - SNDK

    EMC Corp - EMC

    SPDR S&P 500 ETF - SPY

    Dynegy Inc Del - DYN

    Oracle Corporation - ORCL

    MGM Mirage Inc - MGM

    Applied Materials Inc - AMAT

    Advanced Micro Devices - AMD

    QUALLCOMM Inc - QCOM

  • CRWE Network

  •